Pesquisar
Kalaris Therapeutics Inc
KLRSAdicionar à lista de desejos
3.220USD
-0.025-0.77%
Horário de mercado 09/22, 12:07（ET）
76.65MValor de mercado
PerdaP/L TTM
Sobre o {index_name} Kalaris Therapeutics Inc Empresa
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc Perfil
Código da empresaKLRS
Nome da EmpresaKalaris Therapeutics Inc
Data de listagemJul 30, 2020
CEOOxtoby (Andrew)
Número de funcionários6
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 30
Endereço400 Connell Drive
CidadeBERKELEY HEIGHTS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07922
Telefone16502492727
Sitehttps://kalaristx.com/
Código da empresaKLRS
Data de listagemJul 30, 2020
CEOOxtoby (Andrew)
Executivos da empresa Kalaris Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Independent Director
Independent Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
130.55K
--
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Ms. Amy Vandekop
Ms. Amy Vandekop
Interim Principal Accounting Officer
Interim Principal Accounting Officer
948.00
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Independent Director
Independent Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
130.55K
--
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Ms. Amy Vandekop
Ms. Amy Vandekop
Interim Principal Accounting Officer
Interim Principal Accounting Officer
948.00
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Kalaris Therapeutics Inc?
Os cinco principais acionistas de Kalaris Therapeutics Inc são: Dr. Napoleone Ferrara, M.D.